Cited by 5,911Heart Failure Treatment and ManagementCardiac Fibrosis and RemodelingRenin-Angiotensin System Studies

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Results of the Survival and Ventricular Enlargement Trial

Pfeffer, Marc A., Braunwald, Eugene, Moyé, Lemuel A., Basta, Lofty, Brown, Edward J., Cuddy, Thomas E., Davis, Barry R., Geltman, Edward M. +10 more·1992·New England Journal of Medicine

Abstract

Background Left ventricular dilatation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, longterm therapy with the angiotensin-converting--enzyme inhibitor captopril attenuated ventricular dilatation and remodeling. We investigated whether captopril could reduce morbidity and mortality in patients with left ventricular dysfunction after a myocardial infarction. Methods Within 3 to 16 days after myocardial infarction, 2231 patients with ejection fractions of 40 percent or less but without overt heart failure or symptoms of myocardial ischemia were randomly assigned to receive doubleblind treatment with either placebo (1116 patients) or captopril (1115 patients) and were followed for an average of 42 months. Results Mortality from all causes was significantly reduced in the captopril group (228 deaths, or 20 percent) as compared with the placebo group (275 deaths, or 25 percent); the reduction in risk was 19 percent (95 percent confidence interval, 3 to 32 percent; P = 0.019). In addition, the incidence of both fatal and nonfatal major cardiovascular events was consistently reduced in the captopril group. The reduction in risk was 21 percent (95 percent confidence interval, 5 to 35 percent; P = 0.014) for death from cardiovascular causes, 37 percent (95 percent confidence interval, 20 to 50 percent; P less than 0.001) for the development of severe heart failure, 22 percent (95 percent confidence interval, 4 to 37 pe…

Integrity signals

Registry

Crossref · 10.1056/nejm199209033271001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the SAVE study, treatment with captopril reduced the development of heart failure by 37% in asymptomatic people with reduced LVEF after MI.

    “which enrolled asymptomatic people with reduced LVEF after MI, including 23% people with diabetes, treatment with captopril reduced the development of heart failure by 37% (279).”
  • In the SAVE study, treatment with captopril reduced the development of heart failure by 37% in asymptomatic people with reduced LVEF after MI.

    “In the Survival and Ventricular Enlargement (SAVE) study, which enrolled asymptomatic people with reduced LVEF after MI, including 23% people with diabetes, treatment with captopril reduced the development of heart failure by 37% (276).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., Klein, M., Lamas, G. A., Packer, M., Rouleau, J., Rouleau, J. L., Rutherford, J., Wertheimer, J. H., & Hawkins, C. M.
Affiliations
Brigham and Women's Hospital (US)
Venue
New England Journal of Medicine
Published
1992-09-03
Volume
327
Issue
10
Pages
669-677
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2312388685
Cited by
5,911
References
1
Citations by year
2026: 42 · 2025: 66 · 2024: 74 · 2023: 66 · 2022: 94 · 2021: 92 · 2020: 90 · 2019: 81 · 2018: 89 · 2017: 125 · 2016: 126 · 2015: 125 · 2014: 121 · 2013: 122 · 2012: 146
FWCI
227.94
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
captopril, ACE inhibitors, left ventricular dysfunction, myocardial infarction, mortality, morbidity, congestive heart failure, reinfarction, cardiovascular events, ejection fraction, long-term treatment, thrombolysis, aspirin, beta-blockers, left ventricular remodeling, left ventricular dilatation, survival
MeSH terms
Adult, Captopril, Cardiovascular Diseases, Double-Blind Method, Female, Cardiomegaly, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Patient Compliance, Stroke Volume, Survival Rate, Ventricular Function, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review